A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025, due to alleged securities fraud. The complaint asserts that the company and other defendants made false statements or concealed key information regarding its sole drug candidate, SLK. Specifically, it is alleged that SLK and BIMZELX share the same molecular targets, and that SLK's distinct Nanobody structure would not provide superior clinical benefits or increased efficacy as claimed. The suit further alleges that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over traditional monoclonal antibodies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115397) on December 08, 2025, and is solely responsible for the information contained therein.